Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25


A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.

Clin Colorectal Cancer. 2019 Jul 2. pii: S1533-0028(19)30243-9. doi: 10.1016/j.clcc.2019.06.004. [Epub ahead of print]


The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F.

Cancer Immunol Immunother. 2019 Apr;68(4):599-608. doi: 10.1007/s00262-019-02299-8. Epub 2019 Jan 28.


Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.

Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.

Hepatology. 2019 May;69(5):2048-2060. doi: 10.1002/hep.30482. Epub 2019 Mar 10.


Volatile and Contact Chemical Cues Associated with Host and Mate Recognition Behavior of Sphenophorus venatus and Sphenophorus parvulus (Coleoptera: Dryophthoridae).

Duffy AG, Hughes GP, Ginzel MD, Richmond DS.

J Chem Ecol. 2018 Jun;44(6):556-564. doi: 10.1007/s10886-018-0967-8. Epub 2018 May 17.


Billbug (Coleoptera: Dryophthoridae: Sphenophorus spp.) Seasonal Biology and DNA-Based Life Stage Association in Indiana Turfgrass.

Duffy AG, Powell GS, Zaspel JM, Richmond DS.

J Econ Entomol. 2018 Feb 9;111(1):304-313. doi: 10.1093/jee/tox340.


Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.


Treating Hepatobiliary Cancer: The Immunologic Approach.

Duffy AG, Greten TF.

Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3. Review.


Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma.

Duffy AG, Ma C, Ulahannan SV, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner DE, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, Peer CJ, Figg WD, Wood BJ, Greten TF.

Clin Cancer Res. 2017 Aug 15;23(16):4633-4641. doi: 10.1158/1078-0432.CCR-16-3171. Epub 2017 May 2.


Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma.

Duffy AG, Greten TF.

Nat Rev Gastroenterol Hepatol. 2017 Mar;14(3):141-142. doi: 10.1038/nrgastro.2017.7. Epub 2017 Feb 8. No abstract available.


Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.

Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF.

J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.


The case for immune-based approaches in biliary tract carcinoma.

Duffy AG, Makarova-Rusher OV, Greten TF.

Hepatology. 2016 Nov;64(5):1785-1791. doi: 10.1002/hep.28635. Epub 2016 Jun 18. Review.


Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?

Ulahannan SV, Duffy AG.

Hepat Oncol. 2016 Aug;3(3):183-185. doi: 10.2217/hep-2016-0008. Epub 2016 Aug 19. No abstract available.


Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer.

Duffy AG, Makarova-Rusher OV, Ulahannan SV, Rahma OE, Fioravanti S, Walker M, Abdullah S, Raffeld M, Anderson V, Abi-Jaoudeh N, Levy E, Wood BJ, Lee S, Tomita Y, Trepel JB, Steinberg SM, Revenko AS, MacLeod AR, Peer CJ, Figg WD, Greten TF.

Int J Cancer. 2016 Oct 1;139(7):1648-57. doi: 10.1002/ijc.30199. Epub 2016 Jun 27.


Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.

Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, Greten TF, McGlynn KA.

Cancer. 2016 Jun 1;122(11):1757-65. doi: 10.1002/cncr.29971. Epub 2016 Mar 21.


A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib.

Duffy AG, Ulahannan SV, Cao L, Rahma OE, Makarova-Rusher OV, Kleiner DE, Fioravanti S, Walker M, Carey S, Yu Y, Venkatesan AM, Turkbey B, Choyke P, Trepel J, Bollen KC, Steinberg SM, Figg WD, Greten TF.

United European Gastroenterol J. 2015 Oct;3(5):453-61. doi: 10.1177/2050640615583587.


Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T.

JAMA Oncol. 2015 Sep;1(6):787-95. doi: 10.1001/jamaoncol.2015.1790.


The yin and yang of evasion and immune activation in HCC.

Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF.

J Hepatol. 2015 Jun;62(6):1420-9. doi: 10.1016/j.jhep.2015.02.038. Epub 2015 Feb 27. Review.


Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades.

Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF.

Hepat Oncol. 2015 Jan 1;2(1):39-50.


Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage.

Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, Korangy F, Greten TF.

Cancer Immunol Res. 2015 May;3(5):557-66. doi: 10.1158/2326-6066.CIR-14-0182. Epub 2015 Jan 30.


Earlier presentation and application of curative treatments in hepatocellular carcinoma.

Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF.

Hepatology. 2014 Nov;60(5):1637-44. doi: 10.1002/hep.27288. Epub 2014 Sep 29.


Immunological off-target effects of standard treatments in gastrointestinal cancers.

Duffy AG, Greten TF.

Ann Oncol. 2014 Jan;25(1):24-32. doi: 10.1093/annonc/mdt349. Epub 2013 Nov 7. Review.


Hepatocellular carcinoma from an immunologic perspective.

Greten TF, Duffy AG, Korangy F.

Clin Cancer Res. 2013 Dec 15;19(24):6678-85. doi: 10.1158/1078-0432.CCR-13-1721. Epub 2013 Sep 12.


Personalized oncology in interventional radiology.

Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ.

J Vasc Interv Radiol. 2013 Aug;24(8):1083-92; quiz 1093. doi: 10.1016/j.jvir.2013.04.019. Review.


Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.

Clin Cancer Res. 2011 Sep 1;17(17):5755-64. doi: 10.1158/1078-0432.CCR-11-0861. Epub 2011 Jul 12.


Taxane-resistant lymphoepithelial-like carcinoma: excellent response to VIP chemotherapy.

Duffy AG, Wyse G, Horgan AM, O'Keefe M, O'Reilly S, Breathnach OS.

Ir J Med Sci. 2006 Jul-Sep;175(3):64-5.


Supplemental Content

Loading ...
Support Center